Align Clinical CRO: Leading CROs Form New Industry Standards Group to Improve Collaboration with Sponsors
Six leading contract research organizations (CROs) and Veeva Systems (NYSE:VEEV) today introduced Align Clinical CRO, a new industry standards group dedicated to making it easier for sponsors and CROs to work together during clinical trials. Founding members, with input across the industry, plan to help create open technology standards intended to improve trial execution and collaboration with life sciences companies.
For the first time, leading CROs, including ICON plc, Medpace, Pharmaceutical Product Development, LLC (PPD), PRA Health Sciences, Syneos Health, and UBC are coming together to develop open technology standards to transform clinical trial operations across the entire industry to speed product development.
“There is tremendous potential to enhance clinical trial execution with common technology standards that benefit the entire industry,” said Henry Levy, president of Align Clinical CRO. “The assembly of Align Clinical CRO represents an important industry collaboration to improve the trial process and how the industry works together to accelerate drug development.”
Align Clinical CRO will create open technology standards intended to help increase sponsor and CRO productivity, reduce operational costs, and run trials faster. The group’s first standard is anticipated to be an Operational Data Exchange standard to facilitate seamless information sharing between sponsors and CROs. This is expected to include the definition of a technical standard for data to be exchanged between a sponsor and a CRO relating to the operational execution of a trial, including key metrics and milestone information.
CROs play an integral role in supporting drug development, with clinical outsourcing expected to increase to 50% by 2020.1 As sponsors run a growing number of trials with multiple CROs, developing pre-competitive industry standards will help bring more consistency to trial management and address the complexity of trial oversight to make drug development processes more efficient.
Align Clinical CRO will post its Operational Data Exchange standard for public review and input later this year, which will also be reviewed and considered as part of the adoption of proposed standards. Visit AlignClinicalCRO.org to learn about the group’s mission and stay up-to-date on the standards in development.
What Align Clinical CRO Members Are Saying:
“Leading experts are coming together in Align Clinical CRO to streamline how data is shared between CROs and sponsors during trials,” said Thomas O’Leary, chief information officer at ICON plc. “We look forward to contributing to the group and creating standards that drive greater speed and productivity across the industry.”
“Align Clinical CRO will play an important role in helping the industry accelerate innovation and get new treatments to patients faster,” said Mark Roseman, senior vice president of clinical operations at Medpace. “We are excited to join forces with like-minded CROs that want to move the industry forward and make clinical trial execution more efficient.”
“This is the first time CROs are coming together to make this commitment to transform clinical trials across our industry and we are excited to be part of this effort,” said Michael Brooks, executive vice president of product registration at PRA Health Sciences. “This shows our mutual commitment to make the drug development process more efficient and to help bring needed therapies to market more quickly.”
“Align Clinical CRO will help speed the timeline for gaining new therapy approvals for patients,” said Rachel Stahler, chief information officer at Syneos Health. “By creating a vehicle for CROs to collaborate and share actionable insight with sponsors, we can improve operational delivery and streamline the increasingly complex trial process.”
“UBC is excited to join Align Clinical CRO,” said Brett Huselton, senior vice president of commercial strategy for product and opportunity development at UBC. “We are committed to developing open technology standards that benefit the entire industry and make clinical trial processes more efficient.”
About Align Clinical CRO
Align Clinical CRO is an industry standards group founded by Veeva Systems and the world’s largest CROs, including ICON plc, Medpace, Pharmaceutical Product Development LLC (PPD), PRA Health Sciences, Syneos Health, and UBC. The group is dedicated to creating open technology standards that improve trial execution and collaboration with life sciences companies, making it easier for sponsors and CROs to work together during clinical trials. For more information, visit www.alignclinicalcro.org.
1 CRO Industry Primer: A 2016 Credit Suisse Research Analysis, June 2016
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ZephyrTel Welcomes Vasona to Its Portfolio of Software Solutions Serving the Global Telecommunications Sector26.9.2018 10:01 | Pressemelding
ZephyrTel, an ESW Capital software company dedicated to serving the global telecommunications industry, is pleased to announce it has acquired Vasona Networks, a leader in network performance and edge computing software for mobile operators, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005376/en/ Mike Shinya, CEO of ZephyrTel (Photo: Business Wire) ZephyrTel is building a world-class telco practice, to provide a multi-solution and services proposition to the global telco industry and leading enterprises. The company’s primary objective is to offer software and SaaS solutions across telco companies IT estates; from infrastructure right through to customer experience. This, coupled with high levels of industry domain expertise, will enable it to offer consultancy on both business strategy and technology execution. Having already acquired several telecom software companies, ZephyrTel is currently
Hallstar Names Scott Hinkle as New Chief Financial Officer and Head of Global Shared Services26.9.2018 10:00 | Pressemelding
Scott J. Hinkle has joined Hallstar, the global specialty chemistry company, as Chief Financial Officer. He will be based in Hallstar’s corporate headquarters in Chicago, Illinois, reporting directly to Chairman and CEO, John J. Paro. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005216/en/ Hallstar Names Scott Hinkle as New Chief Financial Officer and Head of Global Shared Services (Photo: Business Wire) Founded in 1986, Hallstar has become widely recognized for its innovative expertise in the areas of photostability science, renewable plasticizers, eco-based actives, phthalate replacements, natural olive chemistry and polymer modification. The company boasts research and development, manufacturing, and sales operations in China, Italy, France, and Brazil, in addition to the United States. Hallstar recently announced a structural split into Hallstar Beauty and Hallstar Industrial, effective October 1, 2018. These two
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC26.9.2018 08:00 | Pressemelding
Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC). The survey results will be presented today as a late-breaking abstract (P3.01-108) at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada. The two most important treatment goals identified by those surveyed were increasing overall survival (OS) (77%), followed by quality of life (QoL) (69%), irrespective of the line of treatment. Findings show that more than half (55%) of physicians strongly preferred a treatment sequence that offers patients the maximum time on targeted treatments. Furthermore, physicians reported that there is a strong need for information on potential treatment resistance mutations before changing their current treatment pract
Easy Visual Launches App For Targeted Advertising Reach Through Smartphones26.9.2018 07:00 | Pressemelding
Easy Visual has launched Banners App - a mobile application that shows targeted banners ads to users when they unlock their smartphones. Recent Boston Consulting Group research indicates that consumers spend 25% of their total offline and online media consumption time on mobile phones. However, advertisers spend only 12% of their budgets on mobile ads. Mobile advertising is unappreciated by some brands and it results in a loss of potential clients. Easy Visual has decided to change the situation. 69% of consumers from 18 to 39 years old use smartphones to look for products before buying them. Banners App offer brands and advertisers ads shown only to their target audiences, real views, statistics on the number of views and the conversion rate. Companies get potential customers, brand recognition and better ROI. It avoids brand reputational loss, because users voluntarily look at the advertising messages. Easy Visual is an innovative advertising network that provides advertisers and bra
SoftAtHome Invests in Quality of Experience for Fixed-Mobile Convergence by Acquiring V3D, Leader in Telecom Data Analytics26.9.2018 07:00 | Pressemelding
SoftAtHome, the software company dedicated to the digital home, and V3D, a leading independent software vendor expert on Telecom data analytics for carrier network operators, announced today the signing of an acquisition agreement. With SoftAtHome acquiring V3D, the company will be able to deliver a full range of solutions around “analytics for Quality of Experience” for its fixed and mobile operator clients, by relying on the millions of data points collected by V3D. Thanks to both companies’ expertise, skills and solutions, Carrier Network Operators will benefit from a global value proposition on improving Customer Experience on their fixed and mobile networks. David VIRET-LANGE, Chief Executive Officer of SoftAtHome, commented: “In an increasingly digital world, consumers expect seamless connectivity with their mobile and tablets wherever they are. Quality of Experience will be naturally measured by the same solutions. The V3D solution portfolio and expertise on mobile and fixed net
NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate26.9.2018 06:05 | Pressemelding
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from five studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). “The real-world results from these studies of diverse patient populations on three continents reaffirm the sustained benefits of the UroLift System as an accepted standard of care treatment for patients with BPH,” said Dave Amerson, president of the NeoTract Interventional Urology business unit. “We are pleased that we continue to see results from real-world studies in line with our randomized pivotal study, demonstrating that the UroLift System is a safe and effective minimally invasive treatment that offers men long-term relief from the symptoms of BPH.” Five Studies Show Significant Relief and Improved Quality of Life with UroLift Sy